X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs MYLAN (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   MYLAN
EQUITY SHARE DATA
    NOVARTIS
Mar-18
MYLAN
Dec-14
NOVARTIS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7584,183-   
Low Rs5792,948-   
Sales per share (Unadj.) Rs228.41,431.9-  
Earnings per share (Unadj.) Rs31.7172.5-  
Cash flow per share (Unadj.) Rs32.8277.7-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.1711.8-  
Shares outstanding (eoy) m24.69378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.92.5 117.6%   
Avg P/E ratio x21.120.7 101.9%  
P/CF ratio (eoy) x20.412.8 158.9%  
Price / Book Value ratio x2.25.0 44.9%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5051,348,943 1.2%   
No. of employees `0000.725.0 2.7%   
Total wages/salary Rs m1,4450-   
Avg. sales/employee Rs Th8,441.321,671.6 39.0%   
Avg. wages/employee Rs Th2,163.60-   
Avg. net profit/employee Rs Th1,173.12,610.7 44.9%   
INCOME DATA
Net Sales Rs m5,639541,790 1.0%  
Other income Rs m1,718-3,158 -54.4%   
Total revenues Rs m7,357538,632 1.4%   
Gross profit Rs m-63134,746 -0.0%  
Depreciation Rs m2539,792 0.1%   
Interest Rs m5523,370 0.2%   
Profit before tax Rs m1,57568,426 2.3%   
Minority Interest Rs m0-281 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7922,877 27.5%   
Profit after tax Rs m78465,267 1.2%  
Gross profit margin %-1.124.9 -4.5%  
Effective tax rate %50.34.2 1,195.1%   
Net profit margin %13.912.0 115.4%  
BALANCE SHEET DATA
Current assets Rs m9,522476,305 2.0%   
Current liabilities Rs m3,296372,375 0.9%   
Net working cap to sales %110.419.2 575.5%  
Current ratio x2.91.3 225.8%  
Inventory Days Days3778 46.9%  
Debtors Days Days28107 26.5%  
Net fixed assets Rs m46125,341 0.0%   
Share capital Rs m12319,159 0.6%   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,336269,323 2.7%   
Long term debt Rs m0402,342 0.0%   
Total assets Rs m11,1051,084,807 1.0%  
Interest coverage x29.53.9 750.6%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.50.5 101.7%   
Return on assets %7.68.2 92.5%  
Return on equity %10.724.2 44.1%  
Return on capital %22.213.6 163.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,61071,219 2.3%  
From Investments Rs m687-56,165 -1.2%  
From Financial Activity Rs m-2,677-18,766 14.3%  
Net Cashflow Rs m-380-3,713 10.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.18 Rs / USD

Compare NOVARTIS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: CIPLA  AJANTA PHARMA  SUVEN LIFE  AUROBINDO PHARMA  FDC LTD.  



Today's Market

Nifty Hits Fresh Record High; Sensex Up Over 330 Points(12:30 pm)

After opening the day on a positive note, stock markets in India continued their momentum and went on to scale their record-high levels.

Related Views On News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 20, 2018 03:37 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS